Bank of America’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-744
| Closed | -$1.73K | – | 6760 |
|
|
2025
Q4 | $1.73K | Buy |
744
+11
| +2% | +$26 | ﹤0.01% | 6420 |
|
|
2025
Q3 | $1.38K | Sell |
733
-4,900
| -87% | -$10.8K | ﹤0.01% | 7451 |
|
|
2025
Q2 | $16.3K | Buy |
5,633
+68
| +1% | +$98 | ﹤0.01% | 7096 |
|
|
2025
Q1 | $4.01K | Buy |
5,565
+18
| +0.3% | +$15 | ﹤0.01% | 7250 |
|
|
2024
Q4 | $5.71K | Sell |
5,547
-107
| -2% | -$127 | ﹤0.01% | 7080 |
|
|
2024
Q3 | $7.58K | Buy |
5,654
+96
| +2% | +$129 | ﹤0.01% | 6941 |
|
|
2024
Q2 | $7.22K | Buy |
5,558
+366
| +7% | +$552 | ﹤0.01% | 6951 |
|
|
2024
Q1 | $8.93K | Sell |
5,192
-558
| -10% | -$875 | ﹤0.01% | 6905 |
|
|
2023
Q4 | $8.45K | Sell |
5,750
-3,032
| -35% | -$3.62K | ﹤0.01% | 6926 |
|
|
2023
Q3 | $10.6K | Sell |
8,782
-4,455
| -34% | -$6.17K | ﹤0.01% | 6851 |
|
|
2023
Q2 | $19.2K | Sell |
13,237
-5,180
| -28% | -$8.87K | ﹤0.01% | 6719 |
|
|
2023
Q1 | $26.7K | Buy |
18,417
+10,479
| +132% | +$17.5K | ﹤0.01% | 6676 |
|
|
2022
Q4 | $13.7K | Sell |
7,938
-1,843
| -19% | -$3.44K | ﹤0.01% | 6848 |
|
|
2022
Q3 | $19K | Sell |
9,781
-8,794
| -47% | -$8.74K | ﹤0.01% | 7059 |
|
|
2022
Q2 | $14K | Buy |
18,575
+8,765
| +89% | +$25.5K | ﹤0.01% | 7301 |
|
|
2022
Q1 | $85K | Sell |
9,810
-31,843
| -76% | -$326K | ﹤0.01% | 6943 |
|
|
2021
Q4 | $667K | Buy |
41,653
+27,985
| +205% | +$444K | ﹤0.01% | 5624 |
|
|
2021
Q3 | $251K | Buy |
13,668
+5,967
| +77% | +$95.8K | ﹤0.01% | 6146 |
|
|
2021
Q2 | $107K | Sell |
7,701
-11,118
| -59% | -$155K | ﹤0.01% | 6487 |
|
|
2021
Q1 | $277K | Buy |
18,819
+9,850
| +110% | +$173K | ﹤0.01% | 5799 |
|
|
2020
Q4 | $174K | Sell |
8,969
-6,043
| -40% | -$94.2K | ﹤0.01% | 5685 |
|
|
2020
Q3 | $167K | Sell |
15,012
-1,736
| -10% | -$20.5K | ﹤0.01% | 5400 |
|
|
2020
Q2 | $226K | Buy |
16,748
+6,829
| +69% | +$76.7K | ﹤0.01% | 5160 |
|
|
2020
Q1 | $80K | Sell |
9,919
-8,307
| -46% | -$73.2K | ﹤0.01% | 5641 |
|
|
2019
Q4 | $175K | Buy |
18,226
+3,253
| +22% | +$35.1K | ﹤0.01% | 5707 |
|
|
2019
Q3 | $159K | Buy |
14,973
+3,603
| +32% | +$38K | ﹤0.01% | 5796 |
|
|
2019
Q2 | $131K | Sell |
11,370
-71,069
| -86% | -$856K | ﹤0.01% | 5853 |
|
|
2019
Q1 | $1.05M | Sell |
82,439
-570
| -0.7% | -$6.05K | ﹤0.01% | 4481 |
|
|
2018
Q4 | $510K | Buy |
83,009
+79,123
| +2,036% | +$641K | ﹤0.01% | 4917 |
|
|
2018
Q3 | $41K | Buy |
3,886
+2,005
| +107% | +$23.3K | ﹤0.01% | 6289 |
|
|
2018
Q2 | $28K | Buy |
1,881
+1,422
| +310% | +$18.2K | ﹤0.01% | 6394 |
|
|
2018
Q1 | $6K | Sell |
459
-510
| -53% | -$6.18K | ﹤0.01% | 6738 |
|
|
2017
Q4 | $12K | Buy |
+969
| New | +$11.9K | ﹤0.01% | 6573 |
|
Other funds holding SPRO
GP
P
VCM
AI
AFM
Bank of America's SPRO Position: Q1 2026 in Review
Bank of America sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 744 shares — an estimated $1.73K sold.
Bank of America first reported a position in SPRO in Q4 2017 and held it in 33 quarters. The position peaked at $1.05M in Q1 2019. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.
- Bank of America reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 744 Spero Therapeutics shares in Q1 2026, an estimated $1.73K.
- Bank of America first reported a position in Spero Therapeutics in Q4 2017 and held it in 33 quarters.
- Bank of America's Spero Therapeutics position peaked at $1.05M in Q1 2019.
- 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.